Find a Research Study

We are conducting a research study about visual problems in children with Autism Spectrum Disorder (ASD). We believe that many children with autism may have undiagnosed eye problems because they cannot explain when they have trouble seeing and may not undergo routine eye exams. We hope to develop a method to screen for visual problems in using a new, non-invasive technology called eye tracking. We will use a camera to record your child’s eye movements as they watch video clips for 15-20 minutes.

The purpose of this study is to understand the impact of the COVID-19 pandemic on vulnerable families in Los Angeles, including those caring for a child with special health care needs. Information from this research will be used to understand what the key resource and service needs of families are at this time as well as identify interventions that can be developed or adapted to address these needs.

Our purpose is to look at the long-term neurodevelopmental outcomes of preterm neonatal brain abnormalities.

We are studying how responses to the rotavirus vaccine are influenced by infant nutrition and other exposures in different areas of the world. The information we get from this study may help us to understand how to best protect infants from rotavirus and other infections.

We are studying the role of gut microbiome diversity on the mucosal and systemic responses to Ty21a vaccine. This is to determine if a given microbiota composition is associated with specific immune responses and to evaluate the impact of an oral typhoid vaccination on the human gut microbiota.

Learn about the development of bacterial infections in shunted hydrocephalus.

The purpose of this study is to see how young athletes perform sport tasks and to see what movement patterns are related to future injury risk.

Develop non-invasive measures to identify abnormal placental function in babies with and without congenital anomalies.

To improve patient care and achieve the best health outcomes possible for children with IBD.

To evaluate long-term safety of Humira in pediatric patients (between the ages of 6 and 17 years inclusive at the time of enrollment) with moderately to severely active CD who are prescribed and treated in accordance with the approved local Humira product label under the conditions of routine clinical setting.